UK Renal Registry Chooses InterSystems HealthShare for Chronic Kidney Disease Monitoring and Reporting in Britain

InterSystemsInterSystems, a global leader in software for connected care, today announced that the UK Renal Registry has chosen InterSystems HealthShare® as its new national health informatics platform, gathering data from 84 adult and paediatric renal units, plus satellite haemodialysis units, on over 56,000 patients suffering from stage 5 chronic kidney disease (CKD). HealthShare will allow the Renal Registry to collect near real-time information on patients, helping to improve standards of care across the country through greater data accuracy and more regular, consistent reporting on renal unit performance.

The UK Renal Registry consolidates the collection and analysis of standardised data relating to the incidence, clinical management, and outcome of renal disease to ensure high levels of care at NHS renal units, measured against the standards set by the UK Renal Association. Previously, this information was gathered by disparate IT systems and fed into the UK Renal Registry on a quarterly basis, where it was manually validated, analysed and published in the Registry’s annual report. However, with the implementation of HealthShare, the UK Renal Registry will now:

  • Have a daily data feed
  • Reduce the need for human validation and achieve greater accuracy and consistency of reporting
  • Be able to produce detailed quarterly reports, providing units with greater clarity on their performance
  • More easily track and maintain individual patient records.

Using HealthShare, the Registry will make it easier for clinicians to monitor patient treatment, enabling them to instantly access a patient’s renal data, even if they do not have an existing renal record at that particular treatment centre. This is particularly important for patients moving between transplant and dialysis units and those on holiday, as their treatment can be more accurately tracked and reported, reducing the risk of errors and unnecessary duplicate tests.

Ron Cullen, Director at the UK Renal Registry, said, "The UK Renal Registry is a charitable organisation funded by the NHS and tasked with understanding the care chronic kidney disease patients receive. InterSystems' international reputation and experience with strategic interoperability in healthcare means it is the ideal partner to update our informatics systems nationally and ready our service for the future.

"InterSystems HealthShare will allow us to gather more data, more accurately. The platform will also help us achieve our ambition to expand the registry to over 1 million CKD sufferers, which will include not just stage 5 patients, but also stages 2 to 4. We also hope to use the platform to build new tools for clinicians and patients, such as a medicine reconciliation function, which will improve patient care as well as providing cost savings for the NHS," Cullen added.

Steve Garrington, Vice President, International, InterSystems, commented: "We are delighted that the UK Renal Registry has chosen the InterSystems HealthShare health informatics platform to help clinicians capture, share, understand, and act upon their data in a more timely manner. The Registry provides an invaluable service, and HealthShare will support its goal to improve the quality of care for renal patients in Britain."

The Registry chose HealthShare because of its scalability, the time and cost savings from improved data accuracy, and its ability to provide near real-time data. The implementation is being completed by UK Renal Registry staff.

Related news articles:

About InterSystems
InterSystems develops advanced software technologies that enable breakthroughs. Through its data management, integration, and analytics technologies, InterSystems is dedicated to helping clients and partners succeed by deriving meaning and value from data. InterSystems is the global leader in software for connected healthcare, and industries with extreme performance requirements, including high-volume financial trading, energy, and government, rely on InterSystems software. Founded in 1978, privately held InterSystems is headquartered in Cambridge, Massachusetts (USA), with offices worldwide serving clients and partners in more than 100 countries.

About The Renal Registry UK
The Renal Registry is non-profit making and as part of the Renal Association is registered as a charitable activity by the Charity Commission.

The Registry was established by the Renal Association with support from the Department of Health, the British Association of Paediatric Nephrologists, and the British Transplant Society as a resource for the development of patient care in renal disease. It provides a focus for the collection and analysis of standardised data relating to the incidence, clinical management and outcome of renal disease. The UK Renal Registry monitors indicators of the quality as well as quantity of care, with the aim of improving the standard of care.

The Registry provides data for participating renal units, NHS Trusts, commissioning authorities, regional offices, patient groups and researchers. The development of the Registry is open to influence by all interested parties including clinicians, Trusts, commissioning authorities, patient organisations and researchers.

Most Popular Now

AI Catches One-Third of Interval Breast …

An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published...

NHS National Rehabilitation Centre to De…

The new NHS National Rehabilitation Centre will deploy technology to help patients to maintain their independence as they recover from life-changing injuries and illnesses and regain quality of life. Airwave Healthcare...

AI Tool Accurately Detects Tumor Locatio…

An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a study published...

AI can Accelerate Search for More Effect…

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in...

AI Accurately Classifies Pancreatic Cyst…

Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance Imaging...

Free AI Tools can Help Doctors Read Medi…

A new study from the University of Colorado Anschutz Medical Campus shows that free, open-source artificial intelligence (AI) tools can help doctors report medical scans just as well as more...

Great plan: Now We need to Get Real abou…

The government's big plan for the 10 Year Health Plan for the NHS laid out a big role for delivery. However, the Highland Marketing advisory board felt the missing implementation...

Autonomous AI Agents in Healthcare

The use of large language models (LLMs) and other forms of generative AI (GenAI) in healthcare has surged in recent years, and many of these technologies are already applied in...

Can Amazon Alexa or Google Home Help Det…

Computer scientists at the University of Rochester have developed an AI-powered, speech-based screening tool that can help people assess whether they are showing signs of Parkinson’s disease, the fastest growing...

Researchers Create 'Virtual Scienti…

There may be a new artificial intelligence-driven tool to turbocharge scientific discovery: virtual labs. Modeled after a well-established Stanford School of Medicine research group, the virtual lab is complete with an...

From WebMD to AI Chatbots: How Innovatio…

A new research article published in the Journal of Participatory Medicine unveils how successive waves of digital technology innovation have empowered patients, fostering a more collaborative and responsive health care...

New AI Tool Accelerates mRNA-Based Treat…

A new artificial intelligence (AI) model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various...